Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Xtant Medical Holdings, Inc. (XTNT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Apr 2025, 19:14.
ORBIMED ADVISORS LLC - 10 Apr 2025 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- XTNT
- Reported as of
- 10 Apr 2025
- Net transaction value
- -$30,708,129
- SEC form
- 4
- Accepted by SEC
- 14 Apr 2025, 19:14:36 UTC
- Prior SEC filing
- 11 Apr 2025
- Next SEC filing
- 17 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Xtant Medical Holdings, Inc. (XTNT) on 14 Apr 2025.
Change
- Previous filing in this sequence was filed on 11 Apr 2025.
- Current net transaction value: -$30,708,129.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XTNT
transaction
Common Stock
Sale
- Transaction value
- $23,522,089
- Shares
- -56,004,974
- Change %
- -100%
- Price
- $0.4200
- Shares after
- 0
- Date
- 10 Apr 2025
- Ownership
- See footnotes
- Footnotes
- F1, F3
XTNT
transaction
Common Stock
Sale
- Transaction value
- $7,186,040
- Shares
- -17,109,618
- Change %
- -100%
- Price
- $0.4200
- Shares after
- 0
- Date
- 10 Apr 2025
- Ownership
- See footnotes
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. By virtue of such relationships, OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.
Footnote F2
These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by ORO II.
Footnote F3
This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.